Picture of Zydus Lifesciences logo

ZYDUSLIFE — Zydus Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Zydus Life posts surprise profit rise on strong North American sales

Feb 9 (Reuters) - Indian drugmaker Zydus Lifesciences Ltd ZYDU.NS reported a third-quarter profit above estimates on Monday, underpinned by new drug launches in North America, its biggest market.

The company posted a consolidated profit of 10.42 billion rupees ($115.1 million) for the quarter ended December 31, up from 10.24 billion rupees in the year-ago period.

Analysts, on average, had projected profit to drop to 9.32 billion rupees, as per LSEG-compiled data.

Overall revenue climbed 30.3%, driven by a 16.4% growth in North American sales and nearly a 13% jump in India sales.

KEY CONTEXT

Most Indian generic drugmakers, including Zydus Life, derive a significant portion of their revenue from the U.S. market but have been grappling with weak pricing due to intense competition.

New drug launches, particularly in Zydus' specialty portfolio, have lifted growth in the United States since early 2025. The company launched four more products in the reported quarter.

Meanwhile, Zydus' peers Cipla CIPL.NS and Dr Reddy's REDY.NS reported subdued U.S. sales during the quarter.

PEER COMPARISON

Estimates (next 12 months)Analysts' sentiment
RICEV/EBITDARevenue growth (%)Profit growth (%)Mean rating*# of analystsStock to price target**Div yield (%)
Zydus Lifesciences LtdZYDU.NS14.347.15-10.25Hold290.881.24
Alembic Pharmaceuticals LtdALEM.NS12.3110.6822.55Buy110.811.38
Dr Reddy's Laboratories LtdREDY.NS13.223.29-10.23Hold390.930.64
Cipla LtdCIPL.NS15.097.850.62Hold370.910.98
* The mean of analyst ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT OCTOBER TO DECEMBER STOCK PERFORMANCE -- All data from LSEG -- $1 = 90.5590 Indian rupees ZYDU v Peers https://tmsnrt.rs/3M1Ky7M (Reporting by Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips) ((Kashish.Tandon@thomsonreuters.com; 8800437922;))

Recent news on Zydus Lifesciences

See all news